Last reviewed · How we verify
TimoD implant
At a glance
| Generic name | TimoD implant |
|---|---|
| Also known as | intraocular implant releasing timolol, investigational drug, Intraocular implant releasing timolol, Investigational drug |
| Sponsor | EyeD Pharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Tolerability of a Timolol Releasing Intraocular Implant in Subjects With Primary Open-angle Glaucoma (PHASE1)
- Safety of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract Surgery (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TimoD implant CI brief — competitive landscape report
- TimoD implant updates RSS · CI watch RSS
- EyeD Pharma portfolio CI